Diabetic Gastroparesis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Gastroparesis is characterized by a measurable delay in gastric emptying, devoid of any indications of mechanical blockage. In cases of poorly managed diabetes, diabetic gastroparesis can arise, stemming from disruptions in the autonomic nervous system, neurons, specialized pacemaker cells (interstitial cells of Cajal, ICC) in the stomach and intestine, and the smooth muscle cells in the gastrointestinal tract. Poorly controlled diabetes often leads to hyperglycemia (blood glucose exceeding 200 mg/dL), a contributing factor to diabetic gastroparesis due to neuropathy resulting from prolonged hyperglycemia. Unlike acute hyperglycemia, which can cause delayed gastric emptying but is usually reversible with improved glycemic control, chronic hyperglycemia-associated gastroparesis does not resolve as readily. Gastric emptying hinges on the synchronization of fundal tone and antral phasic contraction, coupled with the simultaneous inhibition of pyloric and duodenal contractions. This coordination relies on interactions between the enteric and autonomic nervous systems, smooth muscle cells, and the specialized pacemaker cells in the stomach (myenteric interstitial cells of Cajal). Initial management of symptomatic gastroparesis frequently involves lifestyle adjustments. Achieving optimal glycemic control in diabetic patients can mitigate the impact of hyperglycemia-induced delayed gastric emptying. Common recommendations include:
• Consuming smaller, more frequent meals
• Minimizing carbonated beverages
• Increasing liquid intake
• Reducing fat and fiber content
Discouraging alcohol and smoking is essential, as they can exacerbate symptoms. The prognosis of diabetic gastroparesis lacks a clear definition and hinges on controlling hyperglycemia and adhering to medications. The condition adversely affects quality of life and can lead to significant morbidity if left unchecked. Educating individuals about the lifelong management of this condition is crucial for improving clinical outcomes. Gastroparesis, a manifestation of autonomic neuropathy, is most prevalent in individuals with diabetes for over a decade and who have already developed other microvascular complications. Once gastroparesis symptoms manifest, they typically endure and remain stable for 12–25 years, even with controlled blood glucose levels. Common symptoms include early satiety, nausea, bloating, abdominal pain, and vomiting. Primary treatments for diabetic gastroparesis involve dietary adjustments, glycemic control, and fluid and electrolyte restoration. For mild cases, dietary modifications are often the initial approach. Estimates suggest that 4% in the U.S. population, 30% in type 2 diabetes (T2DM), and up to 58% in type 1 diabetes (T1DM).
• The age-adjusted incidence rate of gastroparesis is 2.4/100,000 person-years in men and 9.8/100,000 person-years in women.

Thelansis’s “Diabetic Gastroparesis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Gastroparesis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Diabetic Gastroparesis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Diabetic Gastroparesis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Diabetic Gastroparesis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033